Skip to main content
SpringerLink
Log in

Buprenorphine/naloxone cost effective for opioid abuse

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2016 US dollars

  2. opioid use disorder

References

  1. Murphy SM, et al. Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse. Annals of Internal Medicine : 18 Dec 2018. Available from: URL: http://dx.doi.org/10.7326/M18-0227

  2. Barocas JA, et al. Being Explicit About Decisions: Prescribe Medications for Opioid Use Disorder on the Basis of Proven Effectiveness, Not Beliefs. Annals of Internal Medicine : 18 Dec 2018. Available from: URL: http://dx.doi.org/10.7326/M18-3293

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Buprenorphine/naloxone cost effective for opioid abuse. PharmacoEcon Outcomes News 819, 12 (2019). https://doi.org/10.1007/s40274-019-5551-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-5551-0

Search

Navigation